Pfizer’s multi-year lows reflect headwinds, lack of catalysts, and fading appeal to both growth and defensive investors. Read ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer's (NYSE: PFE) shares have been southbound for the better part of three years, partly because it was unable to repeat its incredible financial performance during the early pandemic years. At ...

you probably won't be interested in buying Pfizer stock. And I don't make that assumption based on Pfizer's abysmal performance in recent years. The reality is that the drugmaker faces serious ...